The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients
- 1 November 2017
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 86, 101-105
- https://doi.org/10.1016/j.ejca.2017.09.014
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated MelanomaThe New England Journal of Medicine, 2017
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaThe New England Journal of Medicine, 2017
- Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017European Journal of Cancer, 2017
- Adjuvant ipilimumab in stage III melanoma: New landscape, new questionsEuropean Journal of Cancer, 2016
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant TherapyThe New England Journal of Medicine, 2016
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialThe Lancet Oncology, 2015
- Cutaneous melanomaThe Lancet, 2014
- EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam CriteriaEuropean Journal of Cancer, 2010
- Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus MacrometastasesJournal of Clinical Oncology, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009